Our clinical development strategy for XPOVIO® has been to innovate with the purpose of helping difficult-to-treat patient populations and then expanding into larger patient groups and tumor types. The mechanisms of action of our novel nuclear export inhibitors target a foundational aspect of cancer biology which may allow them to be used against a very wide variety of different tumors. Our development began in hematologic malignancies and we have expanded our clinical trials into a variety of solid tumors.
We see our pipeline of products as a critical partner of choice to be combined with other cancer medicines in a host of different types of cancer.
We began in 2008 with a vision of pioneering a new approach to treating patients with cancer and other serious diseases. Our novel approach to treating cancer involves targeting a cancer cell’s nucleus to prevent the development of a disease. For this reason, our name is based on the suffix ‘karyo’, which means nucleus.
In 2019, we received our first accelerated approval in penta-refractory multiple myeloma. We received a second accelerated approval in 2020 for relapsed or refractory diffuse large B-cell lymphoma (RR DLBCL).
We received an expanded approval for XPOVIO in December of 2020 to now include patients with multiple myeloma as early as first relapse.
We are undertaking numerous clinical trials with a bright future of potential FDA approvals yet to come.
Karyopharm works every day, innovating the science needed to improve the lives of patients with cancer.